1. Post-FDA Approval Results of Epithelium-Off, Full-Fluence, Dresden Protocol Corneal Collagen Crosslinking in the USA
- Author
-
Derick O. Ansah, Jiangxia Wang, Kevin Lu, Samir Jabbour, Kraig S. Bower, and Uri S. Soiberman
- Subjects
Corneal crosslinking ,Outcomes ,Photrexa ,Photrexa viscous ,Post-refractive corneal ectasia ,Progressive keratoconus ,Ophthalmology ,RE1-994 - Abstract
Abstract Introduction The purpose of this non-comparative, prospective, observational study was to evaluate the post-US Food and Drug Administration approval outcomes of epithelium-off, full-fluence, Dresden protocol corneal collagen crosslinking (CXL) for the treatment of progressive keratoconus (KCN) and post-refractive corneal ectasia at a US academic tertiary medical center. Methods This study involved 125 eyes of 97 patients with KCN and 13 eyes of 12 patients with post-refractive ectasia which underwent CXL between November 2016 and September 2019. Best spectacle-corrected visual acuity (BSCVA) and corneal topographic parameters were measured preoperatively, at postoperative month 1 (POM-1), and between postoperative months 3 and 24 (POM 3–24). Results Best spectacle-corrected visual acuity, flat keratometry, steep keratometry, and mean corneal power worsened at POM-1 (p
- Published
- 2020
- Full Text
- View/download PDF